A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC.

Autores
Categoría Estudio primario
Registro de estudiosclinicaltrials.gov
Año 2020
This is a Phase II, international, open-label, two-arm, non-randomised study of AZD4635 in participants with metastatic castration-resistant prostate cancer (mCRPC).
Epistemonikos ID: 3a174498a9099cef54005dbd0d34d710bd1bb0cd
First added on: May 07, 2024